Jefferies Financial Group Inc. acquired a new stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 600,000 shares of the company's stock, valued at approximately $1,590,000. Jefferies Financial Group Inc. owned approximately 2.08% of Aerovate Therapeutics at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Bridgeway Capital Management LLC acquired a new position in Aerovate Therapeutics during the fourth quarter worth $159,000. Braidwell LP acquired a new position in shares of Aerovate Therapeutics during the 4th quarter worth about $3,817,000. Blackstone Inc. bought a new stake in shares of Aerovate Therapeutics in the 4th quarter valued at about $1,324,000. BNP Paribas Financial Markets acquired a new stake in Aerovate Therapeutics in the 4th quarter valued at about $145,000. Finally, Allostery Investments LP bought a new position in Aerovate Therapeutics during the fourth quarter worth about $2,254,000.
Aerovate Therapeutics Trading Up 1.0%
NASDAQ:AVTE traded up $0.08 on Tuesday, hitting $7.42. The company's stock had a trading volume of 301,506 shares, compared to its average volume of 18,406. Aerovate Therapeutics, Inc. has a one year low of $43.75 and a one year high of $884.98. The firm has a market capitalization of $215.07 million, a P/E ratio of -2.48 and a beta of 0.95. The stock has a fifty day moving average of $65.86 and a two-hundred day moving average of $81.40.
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last announced its quarterly earnings results on Friday, April 25th. The company reported ($3.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($10.50) by $7.35. As a group, sell-side analysts anticipate that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current year.
Aerovate Therapeutics Dividend Announcement
The business also recently disclosed a dividend, which was paid on Monday, April 28th. Shareholders of record on Friday, April 25th were paid a dividend of $84.00 per share. The ex-dividend date of this dividend was Tuesday, April 29th.
Aerovate Therapeutics Profile
(
Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
See Also
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
